Alaska Air Group ALK is expanding its network by introducing new routes as it offers the largest summer schedule in its ...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy +) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s ...

A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is ...

An ongoing study showed that 60% of lung cancer patients who took a drug called Lorbrena remained alive and disease-free ...

In the latest trading session, Alaska Air Group (ALK) closed at $41.45, marking a -0.74% move from the previous day.

Lung cancer is the number one cause of cancer-related deaths worldwide. A trial of a new anti-cancer drug has found that five ...

Lorlatinib is a third-generation ALK inhibitor used as standard first-line treatment for patients with ALK-positive NSCLC or ...

ABU DHABI, UNITED ARAB EMIRATES:— Pfizer has announced longer-term follow-up results from the Phase 3 CROWN trial, evaluating ...

Researchers believe the drug could make certain kinds of lung cancers a chronic disease like diabetes, and not necessarily a ...

Walk through Iolani Palace in Honolulu today, and you’ll see glimpses of Hawaii’s past in the building — but nothing like the grandeur of its heyday as the center of Hawaiian political and social life ...

Outgoing Boeing CEO Dave Calhoun will testify before a U.S. Senate panel on June 18 after a series of incidents raised ...

On May 16, 2024, the FDA granted a breakthrough therapy designation to NVL-655, a novel brain-penetrant ALK-selective ...